As of 2025-09-15, the Intrinsic Value of Beam Therapeutics Inc (BEAM) is 501.47 USD. This BEAM valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 20.60 USD, the upside of Beam Therapeutics Inc is 2,334.30%.
The range of the Intrinsic Value is 460.82 - 544.85 USD
Based on its market price of 20.60 USD and our intrinsic valuation, Beam Therapeutics Inc (BEAM) is undervalued by 2,334.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (1,486.05) - (616.25) | (851.33) | -4232.7% |
| DCF (Growth 10y) | (491.19) - (1,020.56) | (635.94) | -3187.1% |
| DCF (EBITDA 5y) | 460.82 - 544.85 | 501.47 | 2334.3% |
| DCF (EBITDA 10y) | 510.28 - 687.72 | 593.71 | 2782.1% |
| Fair Value | -19.70 - -19.70 | -19.70 | -195.63% |
| P/E | (65.25) - (81.88) | (78.41) | -480.6% |
| EV/EBITDA | (49.20) - 626.05 | 200.92 | 875.3% |
| EPV | (31.78) - (41.24) | (36.51) | -277.2% |
| DDM - Stable | (31.50) - (118.25) | (74.88) | -463.5% |
| DDM - Multi | (32.00) - (96.43) | (48.42) | -335.1% |
| Market Cap (mil) | 2,083.90 |
| Beta | 2.14 |
| Outstanding shares (mil) | 101.16 |
| Enterprise Value (mil) | 1,801.76 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.88% |
| Cost of Debt | 6.85% |
| WACC | 8.36% |